Stano-K10 - Kassel Pharma

Following its synthesis in 1959, Stanozolol entered medical practice in 1962 under the name Winstrol. Winthrop Laboratories developed the compound, and Sterling licensed it in the U.S. It was prescribed to manage weight loss, developmental delay, and bone fragility. Unlike testosterone-based steroids, it does not convert to estrogen, making it suitable for patients needing anabolic support without hormonal complications. Although U.S. manufacturing ceased, Stanozolol remains available in countries where steroid regulation permits controlled clinical or veterinary use.

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For detailed information about Stano-K10 by Kassel Pharma, consult with your doctor or healthcare professional.